TCT-292 Three-year clinical outcome of patients treated with the Nobori biolimus-eluting stent and Xience/Promus cobalt-chromium everolimus-eluting stent for unprotected left main disease.

@article{Hiromasa2016TCT292TC,
  title={TCT-292 Three-year clinical outcome of patients treated with the Nobori biolimus-eluting stent and Xience/Promus cobalt-chromium everolimus-eluting stent for unprotected left main disease.},
  author={Takashi Hiromasa and Shoichi Kuramitsu and Hiroyuki Jinnouchi and Takenori Domei and Kyohei Yamaji and Makoto Hyodo and Yoshimitsu Soga and Shinichi Shirai and Kenji Ando},
  journal={Journal of the American College of Cardiology},
  year={2016},
  volume={68 18S},
  pages={B120}
}
BACKGROUND At Aalborg University Hospital, Denmark, we established a dedicated coronary chronic total occlusion (CTO) treatment program in January 2010. From January 2013, retrograde techniques were routinely used. Here we present our clinical CTO treatment results from 2010 to 2012; the pre retrograde approach phase (PRA), and from 2013 to 2016; the… CONTINUE READING